Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer

被引：23

作者：

Han, Xin ^{[1
,2
]}

Zhao, Lijie ^{[1
,2
]}

Xiang, Weiguo ^{[1
,2
]}

Miao, Bukeyan ^{[1
,2
]}

Qin, Chong ^{[1
,2
]}

Wang, Mi ^{[1
,2
]}

Xu, Tianfeng ^{[1
,2
]}

McEachern, Donna ^{[1
,2
]}

Lu, Jianfeng ^{[1
,2
]}

Wang, Yu ^{[1
,2
]}

Metwally, Hoda ^{[1
,2
]}

Yang, Chao-Yie ^{[1
,2
]}

Kirchhoff, Paul D. D. ^{[1
,2
]}

Wang, Lu ^{[5
]}

Matvekas, Aleksas ^{[5
]}

Takyi-Williams, John ^{[5
]}

Wen, Bo ^{[5
]}

Sun, Duxin ^{[5
]}

Ator, Mark ^{[6
]}

Mckean, Robert ^{[6
]}

Wang, Shaomeng ^{[1
,2
,3
,4
]}

机构：

[1] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA

[3] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA

[4] Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA

[5] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA

[6] Oncopia Therapeut Inc, Malvern, PA 19355 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 66卷 / 13期

关键词：

PROTEIN-DEGRADATION; UBIQUITINATION; MOLECULES;

D O I：

10.1021/acs.jmedchem.3c00405

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We report the discovery of ARD-2051as a potent and orally efficaciousandrogen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051achieves DC50 values of 0.6 nM and D (max) >90% in inducing AR protein degradation in both theLNCaPand VCaP prostate cancer cell lines, potently and effectively suppressesAR-regulated genes, and inhibits cancer cell growth. ARD-2051 achievesa good oral bioavailability and pharmacokinetic profile in mouse,rat, and dog. A single oral dose of ARD-2051 strongly reduces AR proteinand suppresses AR-regulated gene expression in the VCaP xenografttumor tissue in mice. Oral administration of ARD-2051 effectivelyinhibits VCaP tumor growth and causes no signs of toxicity in mice.ARD-2051 is a promising AR degrader for advanced preclinical developmentfor the treatment of AR+ human cancers.

引用

页码：8822 / 8843

页数：22

共 50 条

[1] Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
Han, Xin
Wang, Chao
Qin, Chong
Xiang, Weiguo
Fernandez-Salas, Ester
Yang, Chao-Yie
Wang, Mi
Zhao, Lijie
Xu, Tianfeng
Chinnaswamy, Krishnapriya
Delproposto, James
Stuckey, Jeanne
Wang, Shaomeng
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (02) : 941 - 964
[2] Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
Xiang, Weiguo
Zhao, Lijie
Han, Xin
Qin, Chong
Miao, Bukeyan
McEachern, Donna
Wang, Yu
Metwally, Hoda
Kirchhoff, Paul D.
Wang, Lu
Matvekas, Aleksas
He, Miao
Wen, Bo
Sun, Duxin
Wang, Shaomeng
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (18) : 13487 - 13509
[3] Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer
Chen, Linrong
Han, Liuquan
Mao, Shujun
Xu, Ping
Xu, Xinxin
Zhao, Ruibo
Wu, Zhihua
Zhong, Kai
Yu, Guangliang
Wang, Xiaolei
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 216
[4] Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
Han, Xin
Zhao, Lijie
Xiang, Weiguo
Qin, Chong
Miao, Bukeyan
McEachern, Donna
Wang, Yu
Metwally, Hoda
Wang, Lu
Matvekas, Aleksas
Wen, Bo
Sun, Duxin
Wang, Shaomeng
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (17) : 12831 - 12854
[5] Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4
Xiang, Wang
Wang, Qiwei
Ran, Kai
Ren, Jing
Shi, Yaojie
Yu, Luoting
BIOORGANIC CHEMISTRY, 2021, 115
[6] Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
Hu, Jiantao
Hu, Biao
Wang, Mingliang
Xu, Fuming
Miao, Bukeyan
Yang, Chao-Yie
Wang, Mi
Liu, Zhaomin
Hayes, Daniel F.
Chinnaswamy, Krishnapriya
Delproposto, James
Stuckey, Jeanne
Wang, Shaomeng
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (03) : 1420 - 1442
[7] Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer
Chen, Zhixiang
Wang, Mi
Wu, Dimin
Zhao, Lijie
Metwally, Hoda
Jiang, Wei
Wang, Yu
Bai, Longchuan
Mceachern, Donna
Luo, Jie
Wang, Meilin
Li, Qiuxia
Matvekas, Aleksas
Wen, Bo
Sun, Duxin
Chinnaiyan, Arul M.
Wang, Shaomeng
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (07) : 5351 - 5372
[8] Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer
Liu, Quanyu
Tu, Guihui
Hu, Yan
Jiang, Qingna
Liu, Jingwen
Lin, Shanshan
Yu, Zelei
Li, Ge
Wu, Xinhua
Tang, Yuanling
Huang, Xiuwang
Xu, Jianhua
Liu, Yang
Wu, Lixian
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 228
[9] Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase
Sun, Yaoliang
Zhang, Ying
Chen, Xiaoai
Yu, Aisong
Du, Wenhao
Huang, Yuting
Wu, Feifei
Yu, Lei
Li, Jiayi
Wen, Cuiyun
Yang, Hong
Shi, Qiongyu
Geng, Meiyu
Huang, Xun
Xu, Shilin
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 239
[10] Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR plus Human Prostate Cancer
Xiang, Weiguo
Zhao, Lijie
Han, Xin
Xu, Tianfeng
Kregel, Steven
Wang, Mi
Miao, Bukeyan
Qin, Chong
Wang, Mingliang
McEachern, Donna
Lu, Jianfeng
Bai, Longchuan
Yang, Chao-Yie
Kirchhoff, Paul D.
Takyi-Williams, John
Wang, Lu
Wen, Bo
Sun, Duxin
Ator, Mark
Mckean, Robert
Chinnaiyan, Arul M.
Wang, Shaomeng
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (18) : 13280 - 13303

← 1 2 3 4 5 →